Role of modeling and simulation in clinical development of anticancer agentsSPARREBOOM, Alex; KARLSSON, Mats O.Investigational new drugs. 2003, Vol 21, Num 2, issn 0167-6997, 113 p.Serial Issue

A rational approach for selection of optimal covariate-based dosing strategiesJÖNSSON, Siv; KARLSSON, Mats O.Clinical pharmacology and therapeutics. 2003, Vol 73, Num 1, pp 7-19, issn 0009-9236, 13 p.Article

Concentration-controlled or effect-controlled trials useful alternatives to conventional dose-controlled trials?GRAHNEN, Anders; KARLSSON, Mats O.Clinical pharmacokinetics. 2001, Vol 40, Num 5, pp 317-325, issn 0312-5963Article

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drugJÖNSSON, Siv; KARLSSON, Mats O.European journal of pharmaceutical sciences. 2005, Vol 25, Num 1, pp 123-132, issn 0928-0987, 10 p.Article

Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment modelDUVAL, Vincent; KARLSSON, Mats O.Pharmaceutical research. 2002, Vol 19, Num 12, pp 1835-1840, issn 0724-8741, 6 p.Article

Mechanistic models for myelosuppressionFRIBERG, Lena E; KARLSSON, Mats O.Investigational new drugs. 2003, Vol 21, Num 2, pp 183-194, issn 0167-6997, 12 p.Article

Modelling a spontaneously reported side effect by use of a markov mixed-effects modelZINGMARK, Per-Henrik; KAGEDAL, Matts; KARLSSON, Mats O et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2005, Vol 32, Num 2, pp 261-281, issn 1567-567X, 21 p.Article

Assessment of actual significance levels for covariate effects in NONMENWÄHLBY, Ulrika; JONSSON, E. Niclas; KARLSSON, Mats O et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2001, Vol 28, Num 3, pp 231-252, issn 1567-567XArticle

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataKERBUSCH, Thomas; MILLIGAN, Peter A; KARLSSON, Mats O et al.British journal of clinical pharmacology. 2004, Vol 57, Num 2, pp 170-180, issn 0306-5251, 11 p.Article

Pharmacokinetic/pharmacodynamic models for the depletion of vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACSZINGMARK, Per-Henrik; EDENIUS, Charlotte; KARLSSON, Mats O et al.British journal of clinical pharmacology. 2004, Vol 58, Num 4, pp 378-389, issn 0306-5251, 12 p.Article

An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteersLÖNNEBO, Anna; GRAHNKN, Anders; KARLSSON, Mats O et al.British journal of clinical pharmacology. 2007, Vol 64, Num 2, pp 125-132, issn 0306-5251, 8 p.Article

Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXEDJÖNSSON, Siv; KJELLSSON, Maria C; KARLSSON, Mats O et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2004, Vol 31, Num 4, pp 299-320, issn 1567-567X, 22 p.Article

Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesKARLSSON, Mats O; LUTSAR, Irja; MILLIGAN, Peter A et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 3, pp 935-944, issn 0066-4804, 10 p.Article

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the ratMAGNUSSON, Mats O; KARLSSON, Mats O; SANDSTRÖM, Rikard et al.Pharmaceutical research. 2006, Vol 23, Num 3, pp 521-532, issn 0724-8741, 12 p.Article

Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and AdultsFRIBERG, Lena E; RAVVA, Patanjali; KARLSSON, Mats O et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3032-3042, issn 0066-4804, 11 p.Article

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function -evidence of interconversionHAMREN, Bengt; ERICSSON, Hans; SAMUELSSON, Ola et al.British journal of clinical pharmacology. 2008, Vol 65, Num 6, pp 855-863, issn 0306-5251, 9 p.Article

Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects ModelsKJELLSSON, Maria C; OUELLET, Daniele; CORRIGAN, Brian et al.Pharmaceutical research. 2011, Vol 28, Num 10, pp 2610-2627, issn 0724-8741, 18 p.Article

Use of prior information to stabilize a population data analysisGISLESKOG, Per O; KARLSSON, Mats O; BEAL, Stuart L et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2002, Vol 29, Num 5-6, pp 473-505, issn 1567-567X, 33 p.Article

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear RegressionERNEST, C. Steven; HOOKER, Andrew C; KARLSSON, Mats O et al.Pharmaceutical research. 2010, Vol 27, Num 5, pp 866-877, issn 0724-8741, 12 p.Article

Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108 : A potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dogÄBELÖ, Angela; ANDERSSON, Magdalena; HOLMBERG, Ann Aurell et al.European journal of pharmaceutical sciences. 2006, Vol 29, Num 2, pp 91-101, issn 0928-0987, 11 p.Article

Evaluation of type I error rates when modeling ordered categorical data in NONNEMWÄHLBY, Ulrika; MATOLCSI, Katalin; KARLSSON, Mats O et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2004, Vol 31, Num 1, pp 61-74, issn 1567-567X, 14 p.Article

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailabilityKERBUSCH, Thomas; WÄHLBY, Ulrika; MILLIGAN, Peter A et al.British journal of clinical pharmacology. 2003, Vol 56, Num 6, pp 639-652, issn 0306-5251, 14 p.Article

Noninvasive methods to study drug distributionPORT, Ruediger E; WOLFS, Walter.Investigational new drugs. 2003, Vol 21, Num 2, pp 157-168, issn 0167-6997, 12 p.Article

Evaluation of the nonparametric estimation method in NONMEM VISAUIC, Radojka M; KJELLSSON, Maria C; KARLSSON, Mats O et al.European journal of pharmaceutical sciences. 2009, Vol 37, Num 1, pp 27-35, issn 0928-0987, 9 p.Article

Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery diseaseCULLBERG, Marie; ERIKSSON, Ulf G; LARSSON, Marita et al.British journal of clinical pharmacology. 2001, Vol 51, Num 1, pp 71-79, issn 0306-5251Article